Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Equities research analysts at Zacks Research reduced their Q4 2026 earnings estimates for shares of Gilead Sciences in a research report issued on Thursday, May 21st. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $2.07 per share for the quarter, down from their prior forecast of $2.33. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.77) per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2027 earnings at $2.14 EPS, Q3 2027 earnings at $2.35 EPS, Q4 2027 earnings at $2.55 EPS, FY2027 earnings at $9.11 EPS, Q1 2028 earnings at $2.21 EPS and FY2028 earnings at $10.00 EPS.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS.
Read Our Latest Analysis on GILD
Gilead Sciences Stock Performance
Shares of NASDAQ:GILD opened at $130.50 on Friday. The company’s 50 day moving average price is $136.50 and its two-hundred day moving average price is $133.64. Gilead Sciences has a 12-month low of $104.46 and a 12-month high of $157.29. The firm has a market cap of $162.02 billion, a PE ratio of 17.78 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.
Insider Activity at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock valued at $8,523,570 in the last quarter. Insiders own 0.30% of the company’s stock.
Hedge Funds Weigh In On Gilead Sciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paulson Wealth Management Inc. lifted its stake in Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its stake in Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the last quarter. Davidson Trust Co. lifted its stake in Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the last quarter. Alpha Cubed Investments LLC lifted its stake in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the last quarter. Finally, Personal CFO Solutions LLC lifted its stake in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences News Summary
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Maxim Group upgraded Gilead to Buy from Hold and raised its price target to $165, implying meaningful upside from current levels. Maxim Group upgrades Gilead Sciences (GILD)
- Positive Sentiment: Gilead completed its acquisition of Tubulis GmbH, adding next-generation antibody-drug conjugate assets that strengthen its oncology pipeline and could expand future growth opportunities. Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
- Positive Sentiment: New ASCO and EHA 2026 data and upcoming presentations highlight continued momentum in Gilead and Kite’s oncology programs, including antibody-drug conjugates and cell therapy. New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
- Positive Sentiment: Gilead also expanded its collaboration with the World Health Organization to help eliminate visceral leishmaniasis, reinforcing its public-health commitment and corporate reputation. Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis
- Neutral Sentiment: Several articles highlighted Gilead as a profitable large-cap biotech with strong margins and analyst interest, which may support the stock, but these were largely commentary pieces rather than new fundamental catalysts. Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts
- Neutral Sentiment: Gilead launched $3 billion in senior notes, a financing move that is not necessarily negative but may weigh on some investors’ view of leverage and interest expense. Gilead Sciences Launches New $3 Billion Senior Notes
- Negative Sentiment: One earnings-call summary pointed to “deal drag,” suggesting some investors may be focused on near-term integration or transaction costs that could temper enthusiasm despite solid overall results. Gilead Sciences Earnings Call Highlights Growth, Deal Drag
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
